What are the limitations of the nccn ipi?

While the nccn ipi is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the nccn ipi to ensure safe bedside use and optimal diagnostic accuracy.

How does the nccn ipi compare to other Hematology scores?

The nccn ipi is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the nccn ipi free to use?

Yes. OpiCalc provides the nccn ipi completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

927 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

NCCN-IPI

NCCN-IPI: Enhanced granular scoring for DLBCL treated with immunochemotherapy.

Age at Diagnosis

Serum LDH (Normalized Ratio)

Total NCCN-IPI Score

0

Risk Category

Low

Estimated 5-y Overall Survival: 96%

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Prognostication of DLBCL in patients receiving modern R-CHOP immunochemotherapy.

Identifying high-risk patients more accurately than the standard IPI or R-IPI.

Stratification for clinical trials testing augmented therapy in high-risk groups.

Patient Population

Adult patients with newly diagnosed DLBCL. Derived and validated specifically in the rituximab era using the NCCN database.

When Not to Rely on This Score Alone

Non-DLBCL histologies — e.g., Burkitt or Mantle Cell.

CNS-primary lymphoma — although CNS involvement is a risk factor here, primary CNS lymphoma requires a separate staging system (MSKCC).

Section 2

Formula & Logic

Scoring variables

Parameter	Criteria	Points
Age	41 - 60	1
	61 - 75	2
	> 75	3
LDH	1x - 3x ULN	1
	> 3x ULN	2
Ann Arbor Stage	III or IV	1
Extranodal Disease	BM, CNS, Liver/Lung, or GI	1
Performance Status	ECOG ≥ 2	1

Risk Groups (Total 0 - 8)

Score	Risk Group	Estimated 5-y OS
0 - 1	Low	96%
2 - 3	Low-Intermediate	82%
4 - 5	High-Intermediate	64%
≥ 6	High	33%

Section 3

Pearls/Pitfalls

Granularity

NCCN-IPI's granularity in Age and LDH allows it to identify a truly poor-prognosis "High" group (OS 33%) and a "Very Good" Low group (OS 96%) with better discrimination than the original IPI.

Section 4

Evidence Appraisal

Primary Score

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.

Zhou Z et al. • Blood. 2014;123(6):837-42.

View Source

Section 5

Literature

Development

Developed by the National Comprehensive Cancer Network (NCCN) database group to optimize clinical trial design for aggressive lymphoma in the 21st century.

Last Comprehensive Review: 2026

Related Hematology Tools

JAK2V617F Allele Burden Interpreter

Sokal/EUTOS/ELTS Comparison

IPI

R-IPI

Have feedback about this calculator?Let us know.